Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Mucpharm Pty Ltd. is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners, which introduces a variety of examiner perspectives into the prosecution process. Additionally, the portfolio is active in 3 distinct art units, indicating that the company's pharmaceutical innovations are being reviewed across several different specialized groups at the USPTO. This diversity suggests a broad technical scope for the company's current biotechnology patent applications. Navigating 3 distinct art units requires a versatile approach to addressing different sets of prior art and examination guidelines.
IANNUZO, NATALIE NMN is the busiest examiner for the company, with 1 pending office action currently assigned. Given the total of 3 pending office actions, the busiest examiner pending count of 1 shows that the workload is distributed equally among the 3 distinct examiners. This breadth across 3 distinct art units and multiple examiners may require a more varied prosecution strategy than a more centralized portfolio. No single examiner or art unit holds a majority of the company's active pharmaceutical matters. This distributed workload can provide the company with a more resilient patent strategy, as it is not overly dependent on any single examiner or art unit's decision.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 2 | 12.2% | +71.4% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007134 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | IANNUZO, NATALIE NMN | 16d |
| 18705481 | METHODS FOR TREATING RESPIRATORY DISEASES | IANNUZO, NATALIE NMN | — |
| 17922709 | PREVENTING AND TREATING VIRAL INFECTIONS | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007134 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | IANNUZO, NATALIE NMN | 16d |
| 18705481 | METHODS FOR TREATING RESPIRATORY DISEASES | IANNUZO, NATALIE NMN | — |
| 17922709 | PREVENTING AND TREATING VIRAL INFECTIONS | FAN, LYNN Y | — |
| 16975058 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES | FERNANDEZ, SUSAN EMILY | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 1759 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705481 | METHODS FOR TREATING RESPIRATORY DISEASES | IANNUZO, NATALIE NMN | 1653 | §102§103§112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18007134 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | IANNUZO, NATALIE NMN | 1653 | §102§103 | Non-Final OA | 16d | Pending | Jan 27, 2023 |
| 17922709 | PREVENTING AND TREATING VIRAL INFECTIONS | FAN, LYNN Y | 1759 | §103§112 | Final Rejection | — | Pending | Nov 01, 2022 |
| 16975058 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES | FERNANDEZ, SUSAN EMILY | 1651 | §112 | Non-Final OA | — | Pending | Aug 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMucpharm Pty Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Natalie Nmn Iannuzo has the most, with 2 of Mucpharm Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
